Evoke Pharma (NASDAQ:EVOK) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 75 percent increase over losses of $(0.28) per share from the same period last year.
Related Posts
Here’s How Much $1000 Invested In Alphabet 15 Years Ago Would Be Worth Today
Alphabet (NASDAQ:GOOGL) has outperformed the market over the past 15 years by 5.39% on an annualized basis producing…
Snap CEO Hints At Hiring Slowdown, Spending Cuts After Warning Of Q2 Shortfall
Snap, Inc. (NYSE: SNAP) shares tumbled to a two-year low in after-hours trading on Monday after the Snapchat parent company warned that it may miss its second-quarter guidance.
Ocuphire Pharma Announces Last Patient Completes Final Visit In ZETA-1 Phase 2b 24-Week Trial Of Oral APX3330 In Diabetic Retinopathy
Top-line Results are Expected in 4Q 2022
Interim Masked Safety Results Seen Demonstrate Favorable Safety and Tolerability Profile, Consistent with 11 Prior Trials of APX3330
Oral APX3330 has the Potential to Serve a